Flag of the European Union EU Clinical Trials Register Help

Clinical trials for mTOR

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    148 result(s) found for: mTOR. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2021-004010-19 Sponsor Protocol Number: IMEA064 Start Date*: 2021-10-15
    Sponsor Name:IMEA-Fondation Léon M'Ba
    Full Title: Pharmacokinetics of calcineurin & mTOR inhibitors in HIV-1 infected kidney transplant recipients after switch to BIC/FTC/TAF: a pilot study - KINETIK (KIdNEy Transplant bIKtarvy) IMEA 064
    Medical condition: • HIV-1 infected patients > 18 years • Antiretroviral treatment switch to BIC/FTC/TAF decided in standard care by ID physician • Kidney transplant recipient ≥ 3 months • Receiving calcineurin and/o...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004538-14 Sponsor Protocol Number: TACTOR-2013 Start Date*: 2014-07-30
    Sponsor Name:Azienda Ospedaliera Universitaria Integrata Verona
    Full Title: Identification of a specific systemic transcriptome able to differentiate patients with renal transplantation in chronic treatment with tacrolimus from those with mTOR inhibitors.
    Medical condition: Renal Transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022589-29 Sponsor Protocol Number: EP-TSC-624 Start Date*: 2011-03-22
    Sponsor Name:University of Oxford
    Full Title: Investigation of pathways regulating cell survival and early antiangiogenic response to single agent Everolimus or Rapamycin in renal cancer
    Medical condition: Renal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038389 Renal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000952-17 Sponsor Protocol Number: NT13403 Start Date*: 2013-04-29
    Sponsor Name:Prague Psychiatric Centre
    Full Title: The Role of mTOR (Mammalian Target of Rapamycin) Signaling Pathway in the Antidepressive Effect of Ketamine in Patients with Depressive Disorder.
    Medical condition: 1. Men and women at the age between 18 to 65 years, with dextromanual dominance. 2. Patients have to answer DSM IV criteria for the major depressive episode, without psychotic symptoms, on the clin...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10012378 Depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-002834-20 Sponsor Protocol Number: HCC-Rap-001 Start Date*: 2008-01-23
    Sponsor Name:Universitätsklinik für Innere Medizin IV, Klinische Abteilung Gastroenterologie und Hepatologie
    Full Title: Behandlung des fortgeschrittenen hepatozellulären Karzinoms mit dem mTOR-Inhibitor Rapamycin (HCC-Rap-001) Treatment of advanced hepatocellular carcinoma with the mTOR-inhibitor rapamycin (HCC-Ra...
    Medical condition: Advanced hepatocellular carcinoma (HCC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005925-12 Sponsor Protocol Number: polyoma IFB 29 Start Date*: 2011-01-20
    Sponsor Name:Medizinische Hochschule Hannover
    Full Title: Polyomavirus BK nephropathy after renal transplantation: Randomized clinical trial to demonstrate that switching to mTOR inhibitor is more effective than a reduction of immunosuppressive therapy
    Medical condition: Polyoma BK-virus nephropathy is a viral complication after renal transplantation attacking up to 10% of renal transplants and causing transplant failure in 45% of cases. No virustatic treatment exi...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004930-27 Sponsor Protocol Number: MTOR-INHIBITION-SARCOIDOSIS Start Date*: 2019-02-05
    Sponsor Name:Medical University of Vienna
    Full Title: Systems medicine analysis of sarcoidosis by targeting mTOR in a pilot study of sirolimus as treatment in patients with sarcoidosis
    Medical condition: Sarcoidosis with cutaneous affections
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-015459-25 Sponsor Protocol Number: CTKI258A2302 Start Date*: 2010-12-01
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, randomized, multi-center, Phase III study to compare the safety and efficacy of TKI258 versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angioge...
    Medical condition: metastatic renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10038410 Renal cell carcinoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Completed) BE (Completed) ES (Completed) HU (Completed) SK (Completed) IT (Completed) DE (Completed) SE (Completed) AT (Completed) GR (Completed) GB (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2013-004139-62 Sponsor Protocol Number: CRAD001JES13 Start Date*: 2014-01-02
    Sponsor Name:Novartis Farmacéutica S. A.
    Full Title: A pilot open-label, phase II, single-arm study to evaluate the association of biomarkers of hormonal resistance and the mTOR pathway with the clinical efficacy of everolimus plus letrozole in the f...
    Medical condition: Estrogen receptor or progesterone receptor positive locally advanced or metastatic breast cancer in postmenopausal women
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018377-38 Sponsor Protocol Number: MICH Start Date*: 2010-03-12
    Sponsor Name:Leiden University Medical Centre
    Full Title: Immune respons after inactivated oral cholera vaccin (Dukoral) in renal transplant recipients Mucosal response in ImmunoCompromised Host (MICH)
    Medical condition: Single centre, interventional, non-parallel-group trial. Aim: To assess the immunogenicity of inactivated oral cholera vaccine (Dukoral) in renal transplant recipients and healthy controls.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-006702-78 Sponsor Protocol Number: BraimTOR-NEURO Start Date*: Information not available in EudraCT
    Sponsor Name:The Children's Memorial Health Institute
    Full Title: Open, randomized, IInd phase clinical study evaluating the safety and efficacy of rapamycin in the treatment of drug-resistant epilepsy in children with rare and ultra-rare diseases of the central ...
    Medical condition: epilepsy, mTORopathies, focal cortical dysplasia, LEATS
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-004123-20 Sponsor Protocol Number: UCL-ONCO2012-01 Start Date*: 2013-03-11
    Sponsor Name:Centre du Cancer, Cliniques universitaires Saint-Luc
    Full Title: A single arm, multicenter, phase II study of BEZ235 as monotherapy in patients with locally advanced or metastatic Transitional Cell Carcinoma (TCC) after failure of platinum based chemotherapy.
    Medical condition: To treat patients with histollogically- or cytologically-confirmed locally advanced or metastatic TCC not amenable to curative surgery or radiation.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000617-13 Sponsor Protocol Number: TOR-VAX Start Date*: 2022-04-12
    Sponsor Name:Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR)
    Full Title: A prospective, randomized, controlled trial assessing the effect of conversion from Tacrolimus-antimetabolite to Tacrolimus-mTor-inhibitors based immunosuppression to booster SARS-CoV-2-specific se...
    Medical condition: Seroconversion is evaluated after changing treatment from tacrolimus to tacrolimus + mTOR inhibitor in solid organ transplant patients who have not responded to the first three doses of the vaccine
    Disease: Version SOC Term Classification Code Term Level
    21.0 10042613 - Surgical and medical procedures 10080575 Solid organ transplant PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010541-31 Sponsor Protocol Number: MTOR-METAB Start Date*: 2010-10-20
    Sponsor Name:Servicio Nefrología Hospital Universitario de Bellvitge
    Full Title: Efecto de la inhibición de la diana de rapamicina (mTor) sobre el metabolismo y rendimiento en el ejercicio físico
    Medical condition: Pacientes trasplantados renales a los que por indicación clínica se les va a realizar un cambio de un fármaco anti-calcineurínico (Ciclosporina o Tacrolimus) a un inhidor de la diana de rapamicina ...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10038533 Renal transplant LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000655-41 Sponsor Protocol Number: CFTY720A2308 Start Date*: 2005-02-10
    Sponsor Name:Novartis Farmacéutica S.A
    Full Title: A one-year, multicenter, open-label, feasibility study to evaluate the safety and the efficacy of FTY720 5mg introduction and CNI elimination in adult maintenance renal transplant reicpients mainta...
    Medical condition: prevention of acute rejection in maintenance renal transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    7.0 10023439 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-000182-10 Sponsor Protocol Number: CBI-GBM-01 Start Date*: 2006-05-04
    Sponsor Name:Rigshospitalet, Finsen Center
    Full Title: A phase II trial with cetuximab, bevacizumab and irinotecan for patients with malignant glioblastomas and progression after radiation therapy and temozolamid
    Medical condition: Recurrent or progressive primary GBM in patients with performance status (PS) 0-2.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-001193-15 Sponsor Protocol Number: FASTERCC-001 Start Date*: 2016-07-06
    Sponsor Name:Department of Oncology, Aarhus University Hospital
    Full Title: Folic acid supplement versus placebo for treating mucositis adverse events in metastatic renal cell carcinoma patients receiving targeted therapy (FASTERCC). A randomized, double-blind, phase II ...
    Medical condition: Mucositis (nasal, oral, pharyngeal, anal, or genital) is often experienced in relation to TKI and mTOR inhibitor treatment of metastatic renal cell carcinoma patients. The present trial will assess...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004872 10064282 Vaginal mucositis LLT
    20.0 100000004856 10028130 Mucositis oral LLT
    20.0 100000004856 10065721 Anal mucositis LLT
    20.0 100000004867 10028127 Mucositis LLT
    20.0 100000004855 10065881 Pharyngeal mucositis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000675-16 Sponsor Protocol Number: CBEZ235F2201 Start Date*: 2012-09-26
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, two stage, phase II study, evaluating the efficacy of oral BEZ235 plus best supportive care (BSC) versus placebo plus BSC in the treatment of patients with advanced pancreatic neuro...
    Medical condition: Adult patient in advanced pancreatic neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10068916 Pancreatic neuroendocrine tumor metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (Completed) NL (Completed) DE (Completed) IT (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2008-007152-94 Sponsor Protocol Number: 02-2008 Start Date*: 2009-01-30
    Sponsor Name:I.T.M.O. - ITALIAN TRIALS IN MEDICAL ONCOLOGY
    Full Title: Efficacy and Safety of RAD001 (Everolimus) in Patients Affected by Biliary Tract Cancer Progressing After Prior Chemotherapy: a Phase II I.T.M.O. Study
    Medical condition: Patients affected by biliary tract cancer progressing after prior chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10055111 Biliary cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000306-70 Sponsor Protocol Number: 2009/07 Start Date*: 2008-01-29
    Sponsor Name:University of Dundee
    Full Title: The effect of metformin on biomarker activity in primary breast cancer
    Medical condition: Women with histologically proven operable primary, invasive breast cancer of ≥ 1cm in size. The study will involve women from the east of Scotland.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 14:26:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA